Cargando…
Mutations in the MET tyrosine kinase domain and resistance to tyrosine kinase inhibitors in non-small-cell lung cancer
BACKGROUND: The Mesenchymal epithelial transition factor (MET) gene encodes a receptor tyrosine kinase with pleiotropic functions in cancer. MET exon 14 skipping alterations and high-level MET amplification are oncogenic and targetable genetic changes in patients with non-small-cell lung cancer (NSC...
Autores principales: | Yao, Yu, Yang, Huaping, Zhu, Bo, Wang, Song, Pang, Jiaohui, Wu, Xiaoying, Xu, Yang, Zhang, Junli, Zhang, Jinfeng, Ou, Qiuxiang, Tian, Hui, Zhao, Zheng |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9875465/ https://www.ncbi.nlm.nih.gov/pubmed/36698189 http://dx.doi.org/10.1186/s12931-023-02329-1 |
Ejemplares similares
-
Acquired Resistance Mechanism for MET Tyrosine Kinase Inhibitor
por: Fujino, Toshio, et al.
Publicado: (2021) -
Met tyrosine kinase inhibitor, PF-2341066, suppresses growth and invasion of nasopharyngeal carcinoma
por: Zhao, Yuanyuan, et al.
Publicado: (2015) -
Role of the HGF/c-MET tyrosine kinase inhibitors in metastasic melanoma
por: Demkova, Lucia, et al.
Publicado: (2018) -
Outcome of EGFR-mutated NSCLC patients with MET-driven resistance to EGFR tyrosine kinase inhibitors
por: Baldacci, Simon, et al.
Publicado: (2017) -
Conserved regulatory motifs in the juxtamembrane domain and kinase N-lobe revealed through deep mutational scanning of the MET receptor tyrosine kinase domain
por: Estevam, Gabriella O., et al.
Publicado: (2023)